nach oben

Journal of Neuro-Oncology

Erschienen in:

28.07.2017 | Clinical Study

Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival

verfasst von: Christian Henker, Thomas Kriesen, Änne Glass, Björn Schneider, Jürgen Piek

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The potential impact of different radiological features of glioblastoma multiforme (GBM) on overall survival (OS) like tumor volume, peritumoral edema (PTE), necrosis volume, necrosis-tumor ratio (NTR) and edema-tumor ratio (ETR) is still very controversial. To determine the influence of volumetric data on OS und to compare different measuring techniques described in literature. We prospectively evaluated preoperative MR images from 30 patients harboring a primary supratentorial GBM. All patients received gross-total tumor resection followed by standard radiation and chemotherapy (temozolomide). By 3D semi-automated segmentation, we measured tumor volume, necrosis volume, PTE, postoperative residual tumor volume and calculated ETR, NTR and the extent of resection. After critical review of the existing literature we compared alternative measuring techniques with the gold standard of 3D segmentation. Statistical analysis showed a significant impact of the preoperative tumor and necrosis volumes on OS (p = 0.041, respectively p = 0.039). Furthermore, NTR also showed a significant association with OS (p = 0.005). Comparison of previously described measuring techniques and scorings with our results showed that no other technique is reliable and accurate enough as a predictive tool. The critical review of previously published studies revealed mainly inaccurate measurement techniques and patient selection as potential reasons for inconsistent results. Preoperatively measured necrosis volume and NTR are the most important radiological features of GBM with a strong influence on OS. No other measuring techniques are specific enough and comparable with 3D segmentation.

Nur mit Berechtigung zugänglich

Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 16(7):896–913. doi:10.1093/neuonc/nou087 CrossRefPubMedPubMedCentral

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/S1470-2045(09)70025-7 CrossRefPubMed

Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403. doi:10.1016/S1470-2045(14)70011-7 CrossRefPubMed

Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198. doi:10.3171/jns.2001.95.2.0190 CrossRefPubMed

Zinn PO, Mahajan B, Sathyan P et al (2011) Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS ONE 6(10):e25451. doi:10.1371/journal.pone.0025451 CrossRefPubMedPubMedCentral

Grabowski MM, Recinos PF, Nowacki AS et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121(5):1115–1123. doi:10.3171/2014.7.JNS132449 CrossRefPubMed

Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401. doi:10.1016/S1470-2045(06)70665-9 CrossRefPubMed

Li YM, Suki D, Hess K et al (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124(4):977–988. doi:10.3171/2015.5.JNS142087 CrossRefPubMed

Reeves GI, Marks JE (1979) Prognostic significance of lesion size for glioblastoma multiforme. Radiology 132(2):469–471. doi:10.1148/132.2.469 CrossRefPubMed

10.

Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27(1):65–73CrossRefPubMed

11.

Nestler U, Lutz K, Pichlmeier U et al (2015) Anatomic features of glioblastoma and their potential impact on survival. Acta Neurochir 157(2):179–186. doi:10.1007/s00701-014-2271-x CrossRefPubMed

12.

Xue D, Albright RE Jr (1999) Preoperative anaplastic glioma tumor volume effects on patient survival. J Surg Oncol 72(4):199–205CrossRefPubMed

13.

Pierallini A, Bonamini M, Osti MF et al (1996) Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy. Neuroradiology 38(Suppl 1):30

14.

Gutman DA, Cooper LAD, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267(2):560–569. doi:10.1148/radiol.13120118 CrossRefPubMedPubMedCentral

15.

Wangaryattawanich P, Hatami M, Wang J et al (2015) Multicenter imaging outcomes study of the cancer genome atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro Oncol 17(11):1525–1537. doi:10.1093/neuonc/nov117 CrossRefPubMedPubMedCentral

16.

Iliadis G, Kotoula V, Chatzisotiriou A et al (2012) Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer 12:3. doi:10.1186/1471-2407-12-3 CrossRefPubMedPubMedCentral

17.

Crawford FW, Khayal IS, McGue C et al (2009) Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 91(3):337–351. doi:10.1007/s11060-008-9719-x CrossRefPubMed

18.

Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772. doi:10.1158/1078-0432.CCR-12-3002 CrossRefPubMed

19.

Mirimanoff R-O, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569. doi:10.1200/JCO.2005.04.5963 CrossRefPubMed

20.

Eads CA, Danenberg KD, Kawakami K et al (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28(8):E32CrossRefPubMedPubMedCentral

21.

Sawaya R, Hammoud M, Schoppa D et al (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42(5):1044–1055 (discussion 1055-6)CrossRefPubMed

22.

Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8(2):135–160CrossRefPubMed

23.

Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70(4):213–220CrossRefPubMed

24.

Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

25.

Henker C, Kriesen T, Furst K et al (2016) Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme. J Neurooncol 126(3):585–592. doi:10.1007/s11060-015-2005-9 CrossRefPubMed

26.

Liu S-Y, Mei W-Z, Lin Z-X (2013) Pre-operative peritumoral edema and survival rate in glioblastoma multiforme. Onkologie 36(11):679–684. doi:10.1159/000355651 PubMed

27.

Schoenegger K, Oberndorfer S, Wuschitz B et al (2009) Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 16(7):874–878. doi:10.1111/j.1468-1331.2009.02613.x CrossRefPubMed

28.

Wu C-X, Lin G-S, Lin Z-X et al. (2015) Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. Oncol Lett 10(5):2769–2776. doi:10.3892/ol.2015.3639 PubMedPubMedCentral

29.

Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26(10):2466–2474PubMed

30.

Ramnarayan R, Dodd S, Das K et al (2007) Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter. J Neurol Sci 260(1–2):49–56. doi:10.1016/j.jns.2007.04.003 CrossRefPubMed

31.

Li W-B, Tang K, Chen Q et al. (2012) MRI manifestions correlate with survival of glioblastoma multiforme patients. Cancer Biol Med 9(2):120–123. doi:10.3969/j.issn.2095-3941.2012.02.007 PubMedPubMedCentral

32.

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. doi:10.1007/s00401-016-1545-1 CrossRefPubMed

33.

Raza SM, Lang FF, Aggarwal BB et al (2002) Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 51(1):2–12 (discussion 12–3)CrossRefPubMed

34.

Ishii A, Kimura T, Sadahiro H et al (2016) Histological characterization of the tumorigenic “Peri-Necrotic Niche” harboring quiescent stem-like tumor cells in glioblastoma. PLoS ONE 11(1):e0147366. doi:10.1371/journal.pone.0147366 CrossRefPubMedPubMedCentral

35.

Fidoamore A, Cristiano L, Antonosante A et al. (2016) Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug and radioresistance. Stem Cells Int. doi:10.1155/2016/6809105 PubMedPubMedCentral

36.

Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I et al. (2014) When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg 82(1–2):e257–65. doi:10.1016/j.wneu.2014.01.019 CrossRefPubMed

37.

Chen J, Li Y, Yu T-S et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522–526. doi:10.1038/nature11287 CrossRefPubMedPubMedCentral

38.

Eidel O, Burth S, Neumann J-O et al (2017) Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS ONE 12(1):e0169292. doi:10.1371/journal.pone.0169292 CrossRefPubMedPubMedCentral

39.

Odland A, Server A, Saxhaug C et al (2015) Volumetric glioma quantification: comparison of manual and semi-automatic tumor segmentation for the quantification of tumor growth. Acta Radiol 56(11):1396–1403. doi:10.1177/0284185114554822 CrossRefPubMed

40.

Porz N, Habegger S, Meier R et al (2016) Fully automated enhanced tumor compartmentalization: man vs. machine reloaded. PLoS ONE 11(11):e0165302. doi:10.1371/journal.pone.0165302 CrossRefPubMedPubMedCentral

41.

Mazurowski MA, Desjardins A, Malof JM (2013) Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro Oncol 15(10):1389–1394. doi:10.1093/neuonc/nos335 CrossRefPubMedPubMedCentral

Titel: Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival
verfasst von: Christian Henker
Thomas Kriesen
Änne Glass
Björn Schneider
Jürgen Piek
Publikationsdatum: 28.07.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2587-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Distinctive localization and MRI features correlate of molecular subgroups in adult medulloblastoma

Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas

Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis

Prophylactic anticonvulsants in patients with primary glioblastoma